Article
Pharmacokinetics and <i>In vivo</i> Efficacy of Epetraborole against <i>Burkholderia pseudomallei</i>
2025-07-14
Abstract excerpt
Melioidosis, caused by Burkholderia pseudomallei , remains a major therapeutic challenge due to high relapse rates and intrinsic antibiotic resistance. Epetraborole (EBO), a leucyl-tRNA synthetase inhibitor, represents a novel therapeutic approach with a distinct mechanism of action compared to standard-of-care antibiotics. Preclinical studies included MIC determination, pharmacokinetic (PK) profiling, dose range...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 82343527-8d55-57cc-b1d7-bd25b21744d4
- DOI
- 10.1101/2025.07.10.664055
